The study will look at (i) the frequency of clinical ophthalmopathy in Graves´ disease after 12 months treatment with or without diclofenac, (ii) the frequency of progress of clinical signs and symptoms in ophthalmopathy after 12 months treatment with or without diclofenac, and (iii) the frequency of optic neuropathy in clinical ophthalmopathy after 12 months treatment with or without diclofenac.

150 patients with newly diagnosed Graves´disease without ophthalmopathy will be treated with anti-thyroid drugs and L-thyroxin (block and replace) according to clinical routine for 18 months. These patients will be randomized to diclofenac 50 mg twice daily or not for 12 months.

Click here ^[1] for further details.